Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
China Shineway Pharmaceutical Group Limited ( (HK:2877) ) just unveiled an update.
China Shineway Pharmaceutical Group Limited reported a significant decrease in turnover for the first quarter of 2025, with a total revenue of RMB761 million, marking a 31.9% decline compared to the same period in 2024. The company experienced downturns across its product lines, with injection products, soft capsules, granules, and TCM formula granules all seeing substantial reductions in sales, impacting the company’s market positioning and potentially affecting stakeholder confidence.
More about China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the production of various pharmaceutical products, including injection products, soft capsules, granules, and traditional Chinese medicine (TCM) formula granules.
Average Trading Volume: 1,353,123
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.56B
Find detailed analytics on 2877 stock on TipRanks’ Stock Analysis page.